Memantine transdermal patch - Corium International
Alternative Names: Corplex™ MemantineLatest Information Update: 28 May 2022
At a glance
- Originator Corium International
- Class Amines; Analgesics; Antidementias; Antiglaucomas; Antiparkinsonians; Antispastics; Antitussives; Eye disorder therapies; Nitrates; Nootropics; Organic bridged compounds; Small molecules; Vascular disorder therapies
- Mechanism of Action NMDA receptor antagonists; Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In volunteers, In adults) in Australia (Transdermal, Patch)
- 17 Apr 2019 Memantine transdermal patch is still in phase I trials for Alzheimer's disease in Australia (Corium International pipeline, April 2019) (ACTRN12619000574145p)
- 17 Apr 2019 Corium International plans a phase I trial in healthy volunteers in Australia, in May 2019 (Transdermal) (ACTRN12619000574145p)